Xidian Pharmaceutical: Announcement on the company’s receipt of drug registration acceptance notice

Securities code: 301130 Securities abbreviation: West Point Pharmaceutical Announcement number: 2026-060

Jilin Xidian Pharmaceutical Technology Development Co., Ltd.

Announcement regarding the company’s receipt of drug registration acceptance notice

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

Jilin Xidian Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as the "Company") recently received the "Acceptance Notice" for potassium chloride granules issued by the State Food and Drug Administration (hereinafter referred to as the "State Food and Drug Administration"). The State Food and Drug Administration decided to accept the application after review in accordance with the provisions of Article 32 of the "Administrative Licensing Law of the People's Republic of China". The relevant information is now announced as follows:

1. Basic information on applying for registration of drugs

Drug name: Potassium chloride granules

Category: Chemicals

Dosage form: granules

Specifications: Each bag contains 1.5g of potassium chloride

Acceptance number: CYHB2601567

Application matters: Supplementary application for domestically produced drugs: Supplementary application matters for approval by the national drug regulatory department; 3. Change of drug marketing authorization holder.

Registration Applicant: Jilin Xidian Pharmaceutical Technology Development Co., Ltd.

Review conclusion: According to the provisions of Article 32 of the "Administrative Licensing Law of the People's Republic of China", after review, it is decided to accept the application.

2. Introduction to drug-related situations

Potassium chloride granules are mainly used to treat and prevent hypokalemia, including conditions with or without metabolic alkalosis.

3. Situation of similar drugs

According to the website of the State Food and Drug Administration, as of the date of this announcement, 43 domestic pharmaceutical manufacturers have obtained registration approval for potassium chloride granules.

4. Impact on the company and risk warning

According to relevant national regulations, the above-mentioned drugs have been accepted for registration and submitted to the Drug Evaluation Center of the State Food and Drug Administration for review and approval. The receipt of the acceptance notice for the above-mentioned drugs will not have an impact on the company's recent performance. The time and results of obtaining the registration approval documents for the relevant drugs are uncertain. The company will actively promote the progress of the project and promptly perform its information disclosure obligations on the subsequent progress of the project. Investors are advised to make prudent decisions and pay attention to investment risks.

5. Documents for reference

"Notice of Acceptance".

Announcement is hereby made.

Board of Directors of Jilin Xidian Pharmaceutical Technology Development Co., Ltd.

August 20, 2026